Austar Lifesciences Limited
HKEX:6118.HK
0.62 (HKD) • At close November 12, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,763.734 | 2,228.644 | 2,015.028 | 1,295.98 | 1,049.021 | 816.585 | 546.933 | 672.545 | 627.544 | 679.75 | 705.153 |
| Cost of Revenue
| 1,427.684 | 1,765.975 | 1,536.02 | 972.45 | 764.777 | 612.191 | 425.401 | 512.838 | 473.297 | 451.143 | 490.187 |
| Gross Profit
| 336.05 | 462.669 | 479.008 | 323.53 | 284.244 | 204.394 | 121.532 | 159.707 | 154.247 | 228.607 | 214.966 |
| Gross Profit Ratio
| 0.191 | 0.208 | 0.238 | 0.25 | 0.271 | 0.25 | 0.222 | 0.237 | 0.246 | 0.336 | 0.305 |
| Reseach & Development Expenses
| 55.332 | 70.163 | 65.598 | 48.268 | 42.577 | 30.308 | 26.062 | 32.041 | 26.908 | 23.594 | 23.897 |
| General & Administrative Expenses
| 133.666 | 134.614 | 128.094 | 98.695 | 108.731 | 77.45 | 70.796 | 67.953 | 56.213 | 57.278 | 47.849 |
| Selling & Marketing Expenses
| 167.323 | 178.659 | 170.289 | 148.692 | 137.077 | 105.635 | 100.473 | 82.687 | 71.002 | 65.134 | 72.104 |
| SG&A
| 300.989 | 310.121 | 304.076 | 259.322 | 250.948 | 183.085 | 171.419 | 150.79 | 127.215 | 122.412 | 119.953 |
| Other Expenses
| -0.307 | -2.797 | 2.284 | 3.027 | 0.42 | 0.256 | 0.414 | 0.414 | 0 | 0 | 0 |
| Operating Expenses
| 345.064 | 368.21 | 156.852 | 282.363 | 274.39 | 204.524 | 183.061 | 180.208 | 148.068 | 140.209 | 138.664 |
| Operating Income
| -29.994 | 90.392 | 116.968 | 26.381 | 2.651 | -6.015 | -68.12 | -20.533 | 4.534 | 84.654 | 71.888 |
| Operating Income Ratio
| -0.017 | 0.041 | 0.058 | 0.02 | 0.003 | -0.007 | -0.125 | -0.031 | 0.007 | 0.125 | 0.102 |
| Total Other Income Expenses Net
| 1.85 | -3.907 | 202.257 | 15.108 | 9.557 | 9.513 | 9.7 | 3.032 | 3.056 | 3.171 | 4.765 |
| Income Before Tax
| -34.41 | 86.485 | 319.225 | 41.489 | 12.208 | 3.498 | -58.42 | -17.501 | 7.59 | 87.825 | 76.653 |
| Income Before Tax Ratio
| -0.02 | 0.039 | 0.158 | 0.032 | 0.012 | 0.004 | -0.107 | -0.026 | 0.012 | 0.129 | 0.109 |
| Income Tax Expense
| 0.379 | 18.741 | 46.601 | 9.884 | 4.744 | 3.378 | 4.223 | 1.169 | 1.207 | 22.632 | 23.082 |
| Net Income
| -113.473 | 87.461 | 277.3 | 33.1 | 8.091 | 0.107 | -54.085 | -18.67 | 6.384 | 65.193 | 53.571 |
| Net Income Ratio
| -0.064 | 0.039 | 0.138 | 0.026 | 0.008 | 0 | -0.099 | -0.028 | 0.01 | 0.096 | 0.076 |
| EPS
| -0.22 | 0.17 | 0.54 | 0.065 | 0.016 | 0 | -0.11 | -0.036 | 0.013 | 0.17 | 0.14 |
| EPS Diluted
| -0.22 | 0.17 | 0.54 | 0.06 | 0.016 | 0 | -0.11 | -0.036 | 0.01 | 0.17 | 0.14 |
| EBITDA
| 52.939 | 106.07 | 130.621 | 39.83 | 14.4 | 1.558 | -60.206 | -9.657 | 14.484 | 91.97 | 77.603 |
| EBITDA Ratio
| 0.03 | 0.048 | 0.065 | 0.031 | 0.014 | 0.002 | -0.11 | -0.014 | 0.023 | 0.135 | 0.11 |